title: Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model.
abstract: Nanoliposomes are good drug delivery systems that allow the encapsulation of drugs into vesicles for their delivery. The objective of this study is to investigate the therapeutic efficacy of a new radio-therapeutics of (188)Re-labeled pegylated liposome in a C26 murine colon carcinoma solid tumor model. The safety of (188)Re-liposome was evaluated before radiotherapy treatment. The anti-tumor effect of (188)Re-liposome was assessed by tumor growth inhibition, survival ratio and ultrasound imaging. Apoptotic marker in tumor was also evaluated by the TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling) method after injection of (188)Re-liposome. The group treated with (188)Re-liposome displayed slight loss in body weight and decrease in white blood cell (WBC) count 7 to 14 days post-injection. With respect to therapeutic efficacy, the tumor-bearing mice treated with (188)Re-liposome showed better mean tumor growth inhibition rate (MGI) and longer median survival time (MGI = 0.140; 80 day) than those treated with anti-cancer drug 5-FU (MGI = 0.195; 69 day) and untreated control mice (MGI = 0.413; 48 day). The ultrasound imaging showed a decrease in both tumor volume and number of blood vessels. There were significantly more apoptotic nuclei (TUNEL-positive) in (188)Re-liposome-treated mice at 8 h after treatment than in control mice. These results evidenced the potential benefits achieved by oncological application of the radio-therapeutics (188)Re-liposome for adjuvant cancer treatment.
authors.affiliation: Institute of Nuclear Energy Research, 1000 Wenhua Road, Chiaan Village, Lungtan, Taoyuan, Taiwan, Republic of China.
authors.forename: Ya-Jen
authors.initials: YJ
authors.lastname: Chang
authors.forename: Chin-Wei
authors.initials: CW
authors.lastname: Hsu
authors.forename: Chih-Hsien
authors.initials: CH
authors.lastname: Chang
authors.forename: Keng-Li
authors.initials: KL
authors.lastname: Lan
authors.forename: Gann
authors.initials: G
authors.lastname: Ting
authors.forename: Te-Wei
authors.initials: TW
authors.lastname: Lee
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D005029:Ethylenediamines / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007275:Injections, Intravenous; D007553:Isotope Labeling; D008081:Liposomes / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D016019:Survival Analysis; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: C521828:188Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine; D005029:Ethylenediamines; D008081:Liposomes; D009942:Organometallic Compounds; D005472:Fluorouracil